Ketogenic diet attenuates cerebellar atrophy progression in a subject with a biallelic variant at the ATAD3A locus [Response to Letter]

This article was published in the following Dove Press journal:
The Application of Clinical Genetics

Ashraf Al Madhoun^{1,2}
Fahad Alnaser³
Motasem Melhem¹
Rasheeba Nizam¹
Tala Al-Dabbous⁴
Fahd Al-Mulla¹

¹Genetics and Bioinformatics
Department, Dasman Diabetes Institute,
Dasman, 15462 Kuwait City, Kuwait;

²Animal and Imaging Core Facility
Department, Dasman Diabetes Institute,
Dasman, 15462 Kuwait City, Kuwait;

³Radiology Department, Ibn Sina
Hospital, Ministry of Health, Kuwait City,
Kuwait; ⁴Bayt Abdullah Children's
Hospice, NBK Children's Cancer
Hospital, Al-Adan ICU, Kuwait City,
Kuwait

Dear editor

It is with great interest to read the comments of Dr. Josef Finsterer on our recent article, "Ketogenic diet attenuates cerebellar atrophy progression in a subject with a biallelic variant at the ATAD3A locus by Al Madhoun et al, 2019," which has received a substantial article-level metrics and respond to the queries raised single nucleotide polymorphisms and deletion mutations within ATAD3 are lethal at embryonic stage or postnatally and the few survivors are living with low quality of life.¹⁻³ Accordingly, ATAD3 genotyping enable prediction of genotype/phenotype relationship.

Desai et al (2017) associated ATAD3 function with cholesterol homeostasis and maintenance of the mitochondrial genome stability.⁴ We thought that Ketogenic Diet (KD) may modulate mitochondrial biogenesis especially that it has proven efficacy in mitochondriopathies-mediated neurological disorders.^{5,6} Thus, it is not unrealistic to include KD treatment in a disease that is caused by ATAD3 gene mutations.

The girl described in our paper is unique. She has been clinically evaluated extensively in Canada, but unfortunately, the family was not given a formal diagnosis. We diagnosed her with Harel-Yoon syndrome after discovering a novel pathogenic missense homozygous mutation in the ATAD3 gene (rs546711654 c.251C>T; p.Thr84Met). Globally, the variant allele frequency of rs546711654 is 0.0002 (<https://www.ncbi.nlm.nih.gov/clinvar/variation/452865/>). This information means that the disease is rare and therefore it is not possible to study other children harboring the same mutation.

In response to KD, we never claimed an increase in the relative sagittal length of the cerebellum. But rather, an obvious slowing of her cerebellar atrophy. The KD was applied between the 2nd and 3rd MRI examination at the age of 4 and 5.5 years old. It has been reported that KD lowers the blood pH, increases ATP by shifting from glucose- to ketone-based metabolism.⁷ Although all body tissues are influenced by KD, the most prominent effect is on the nervous system activities.^{8,9} Accordingly, we do not exclude a positive effect on the muscle function.

KD increases mitochondrial biogenesis.^{10,11} We agree that a real-effect of KD can only be assessed reliably in double-blind randomized clinical trials, but this is

Correspondence: Fahd Al-Mulla
Head of Genetics and Bioinformatics
Department, Dasman Diabetes Institute,
Dasman, 15462 Kuwait City, Kuwait
Tel +9 652 224 2999 Ext. 2211
Email fahd@al-mulla.org

obviously not possible in very rare cases such as ours. However, the parents were surprised with the improved quality of life of the child.

Science starts with an observation, which is then propagated through well-defined experimental procedures that address precise research questions. Our observation is a start and we look forward to learn how other children with cerebellar atrophy may benefit from our experience.

As we clearly mentioned in the manuscript, the patient suffered from frank ataxia and intentional tremor secondary to her cerebellar atrophy. However, clinically she had clear pill-rolling resting tremor. In our experience, children with parkinsonism do not necessarily present with classical Parkinson's disease symptoms. Neither DATScan test was performed nor L-DOPA was administered since compared to her other symptoms, particularly the severe osteoporosis, ataxia and intentional tremor, the parkinsonian tremor appeared minor. The functional neurological assessments included drawing, holding arms outstretched, gait and body posture and coordination.¹² The patient did not suffer from epilepsy.

No peripheral neuropathy was observed. Nerve conduction study revealed normal response at the peroneal and tibial terminal motor latency (1.95 ± 0.24 ms), M-wave amplitudes were 3.6 ± 0.2 mV and 8.5 ± 1.1 mV, respectively, average duration 8.1 ± 0.14 and the F-M wave latency was 20.7 ± 0.6 .

The patient, as expected, in Harel-Yoon syndrome had bilateral cataract and no optic hypoplasia was observed in the subject. In Harel et al study, optic atrophy was detected in some patients, but not all¹ other symptoms included congenital cataract, corneal cloudy and photophobia.^{1,2,13} No functional retinal tests were performed.

It is important to note that the patient, during her long journey of diagnosis, has endured significant stress. Although we wish to perform many tests on her, we need to be diligent in our choices of tests. The family as mentioned above were disappointed with the lack of diagnosis after many years of laborious investigations, which culminated in more trauma, psychological and physical stress and were very rightly reluctant to undertake further tests. This is understandable. Moreover, mitochondria are present in every cell, while cerebellar atrophy appears to be the most likely presentation because of the high energy demand of neurons, one cannot exclude the possibility of

pathologies in the muscle (myopathy), bone cells (osteoporosis), bone marrow, intestinal cells, etc. We are confident given our final diagnosis that the patients will have pathologies everywhere. Osteoporosis, bone fractures and osteomyelitis are now the major threat to the patient. When would one stop investigating?

Disclosure

The authors report no conflicts of interest in this communication.

References

- Harel T, Yoon WH, Garone C, et al. Recurrent de novo and biallelic variation of ATAD3A, encoding a mitochondrial membrane protein, results in distinct neurological syndromes. *Am J Hum Genet.* 2016;99(4):831–845. doi:10.1016/j.ajhg.2016.08.007
- Cooper HM, Yang Y, Ylikallio E, et al. ATPase-deficient mitochondrial inner membrane protein ATAD3A disturbs mitochondrial dynamics in dominant hereditary spastic paraplegia. *Hum Mol Genet.* 2017;26:1432–1443. doi:10.1093/hmg/ddx042
- He J, Cooper HM, Reyes A, et al. Mitochondrial nucleoid interacting proteins support mitochondrial protein synthesis. *Nucleic Acids Res.* 2012;40:6109–6121. doi:10.1093/nar/gks266
- Desai R, Frazier AE, Durigon R, et al. ATAD3 gene cluster deletions cause cerebellar dysfunction associated with altered mitochondrial DNA and cholesterol metabolism. *Brain.* 2017;140:1595–1610. doi:10.1093/brain/awx094
- Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. *Cochrane Database Syst Rev.* 2012;(3):Cd001903. doi:10.1002/14651858
- Paoli A, Bianco A, Damiani E, Bosco G. Ketogenic diet in neuromuscular and neurodegenerative diseases. *Biomed Res Int.* 2014;2014:474296.
- Yudkoff M, Daikhin Y, Nissim I, Lazarow A, Nissim I. Ketogenic diet, brain glutamate metabolism and seizure control. *Prostaglandins Leukot Essent Fatty Acids.* 2004;70:277–285. doi:10.1016/j.plefa.2003.07.005
- Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. *Physiol Rev.* 1980;60:143–187. doi:10.1152/physrev.1980.60.1.143
- Masood W, Uppaluri KR. *Ketogenic Diet*. Treasure Island, FL: StatPearls; 2019.
- Hasan-Olive MM, Lauritzen KH, Ali M, Rasmussen LJ, Storm-Mathisen J, Bergersen LH. A ketogenic diet improves mitochondrial biogenesis and bioenergetics via the PGC1alpha-SIRT3-UCP2 axis. *Neurochem Res.* 2019;44:22–37. doi:10.1007/s11064-018-2588-6
- Bough KJ, Wetherington J, Hassel B, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. *Ann Neurol.* 2006;60:223–235. doi:10.1002/ana.20899
- Puschmann A, Wszolek ZK. Diagnosis and treatment of common forms of tremor. *Semin Neurol.* 2011;31:65–77. doi:10.1055/s-0031-1271312
- Al Madhoun A, Alnaser F, Melhem M, Nizam R, Al-Dabbous T, Al-Mulla F. Ketogenic diet attenuates cerebellar atrophy progression in a subject with a biallelic variant at the ATAD3A locus. *Appl Clin Genet.* 2019;12:79–86. doi:10.2147/TACG.S194204

Dove Medical Press encourages responsible, free and frank academic debate. The content of the The Application of Clinical Genetics 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the The Application of Clinical Genetics editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

The Application of Clinical Genetics

Dovepress

Publish your work in this journal

The Application of Clinical Genetics is an international, peer-reviewed open access journal that welcomes laboratory and clinical findings in the field of human genetics. Specific topics include: Population genetics; Functional genetics; Natural history of genetic disease; Management of genetic disease; Mechanisms of genetic disease;

Counselling and ethical issues; Animal models; Pharmacogenetics; Prenatal diagnosis; Dysmorphology. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/the-application-of-clinical-genetics-journal>